Clinical Research Progress of Hetrombopag in Thrombocytopenia
ABSTARCT:Thrombocytopenia is a disorder characterized by a decreased platelet count in the peripheral blood,which can be caused by various congenital and acquired diseases.Currently,thrombopoiesis-promoting drugs used for thrombocytopenia primarily include re-combinant human interleukin-11(rhIL-11),recombinant human thrombopoietin(rhTPO),and thrombopoietin receptor agonist(TPO-RA).Hetrombopag is an innovative oral non-peptide TPO-RA that has been approved for treating chronic adult primary immune throm-bocytopenia(ITP)with inadequate response to glucocorticoids and immunoglobulin,as well as severe aplastic anemia(SAA)with poor response to immunosuppressive therapy in China.Clinical studies have demonstrated that hetrombopag is safe and well-tolerated in ITP and SAA patients.Currently,there is an ongoing phase Ⅲ clinical trial investigating the efficacy of hetrombopag in managing chemotherapy-induced thrombocytopenia(CIT).This article provides a review on the research progress of hetrombopag in treating thrombocytopenia,aiming to offer valuable insights for clinical practice.
NETL
NSTL
万方数据
